

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number
WO 2005/007669 A1

(51) International Patent Classification:
113/00, 51/00, A61K 31/575, A61P 31/04

C07J 9/00,

(74) Agent: THALSØ-MADSEN, Birgit; Head of Patent
Section, Leo Pharma A/S, Industriparken 55, DK-2750
Ballerup (DK).

(21) International Application Number:

PCT/DK2004/000491

(22) International Filing Date: 9 July 2004 (09.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

PA 2003 01080	16 July 2003 (16.07.2003)	DK
60/487.609	17 July 2003 (17.07.2003)	US
PA 2003 01486	9 October 2003 (09.10.2003)	DK

(71) Applicant (for all designated States except US): LEO
PHARMA A/S [DK/DK]; Industriparken 55, DK-2750
Ballerup (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DUVOLD, Tore
[NO/DK]; Thorvaldsenvej 21, 4.th, DK-1871 Frederiks-
berg C (DK). BRETTEING, Claus, Aage, Svensgaard
[DK/DK]; Smallegade 42, 4.tv, DK-2000 Frederiksberg
(DK). RASMUSSEN, Poul, Rødbroe [DK/DK]; Harevej
2, DK-3600 Frederikssund (DK). BOUÉRAT, Laetitia
[FR/DK]; Bille Brahes Vej 12, 4.tv, DK-1963 Frederiksberg
C (DK). THORHAUGE, Jacob [DK/DK]; Drosselvænget
13, DK-2750 Ballerup (DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL FUSIDIC ACID DERIVATIVES



(57) Abstract: The present Invention relates to novel fusidic acid
derivatives of general formula [I] wherein X represents halogen,
trifluoromethyl, cyano, azido, alkyl, alkenyl or aryl, wherein
alkyl, alkenyl or aryl are optionally substituted by one or more, same
or, different substituents selected from the group consisting of alkyl,
alkenyl, aryl, alkoxy, nitro, alkylthio, halogen, azido, trifluoromethyl
and cyano; Y and Z both represent hydrogen, or together with the
C-17/C-20 bond form a double bond between C-17 and C-20, or together
are methylene and form a cyclopropane ring in combination with C-17
and C-20; A represents a bond, O, S or S(O); B represents C₁₋₆ alkyl,
C₂₋₆ alkenyl, C₁₋₆ acyl, C₃₋₇ cycloalkylcarbonyl or benzoyl, all of which
are optionally substituted with one or more substituents selected from
the group consisting of halogen, hydroxy, alkoxy, aryl, heteroaryl and
azido, or, if A represents a bond, B may also represent hydrogen; Q1
and Q2 independently represent -CH₂-, -C(O)-, -(CHOR)-, -(CHOR)-,
-(CHSH)-, -(NH)-, -(CHNH₂)- or -(CHW)-, wherein R represents
C₁₋₆alkyl and W represents halogen, cyano, azido or trifluoromethyl; Q3

represents -CH₂-, -C(O)- or -CHOH-; G represents hydrogen, OH or O-CO-CH₃; two bonds in the pentacyclic ring being depicted
with full and dotted lines to indicate that either of the two bonds may be a double bond, in which case Y is absent and Z represents
hydrogen; the bond between C-1 and C-2 being either a single or a double bond; and pharmaceutically acceptable salts and easily
hydrolysable esters thereof, to pharmaceutical compositions comprising said derivatives, as well as to their use in therapy.

WO 2005/007669 A1